Search Results

Displaying Results 1-1 of 1 "'CADL'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

Oct 14, 2025, 08:10 ET Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

Candel Therapeutics, Inc. (Nasdaq: CADL) ("Candel"), a clinical-stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer.

More news about: Trinity Capital Inc.

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.